Pharmacyte Biotech Inc (PMCB) Return on Investment ROI from the first quarter of 2026 to first quarter of 2026 and for the year 2026, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Pharmacyte Biotech Inc   (NASDAQ: PMCB)


Pharmacyte Biotech Inc's ROI from its first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Pharmacyte Biotech Inc's ROI in the first quarter of 2026?
Pharmacyte Biotech Inc recorded a cumulative net loss of $-16 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -36.06%.

Within the Healthcare sector 400 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2026 from 3553 to 3698.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jul 31 2026)
I. Quarter		 (Apr 30 2026)
IV. Quarter		 (Jan 31 2026)
III. Quarter		 (Oct 31 2025)
II. Quarter		 (Jul 31 2025)
I. Quarter
Y / Y Investment Change TTM -8.97 % -11.99 % -7.51 % -15.26 % -23.87 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 34 42 52 53 44
Return On Investment (TTM) -36.06 % -40.95 % -12.79 % -20.09 % -9.12 %
PMCB's Overall Ranking # 3698 # 3553 # 2897 # 3116 # 2741
Seq. Investment Change TTM -5.43 % -4.95 % -0.11 % 1.39 % -8.57 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -16 -20 -6 -10 -5

PMCB Company Profile >> Back to PMCB Roi Comparisons >> See Annual PMCB Return On Investment



Return On Investment PMCB's Ranking
Within: No.
Industry # 50
Sector # 401
Overall # 3698

Return On Investment Statistics
High Average Low
48.77 %
-171.17 %
-3118.74 %
(Apr 30 2025)   (Oct 31 2013)







Financial Statements
Pharmacyte Biotech Inc's I. Quarter Investments $ 34 Millions PMCB's Balance sheet
Pharmacyte Biotech Inc's I. Quarter Income $ -5 Millions Quarterly PMCB's Income Statement
PMCB's Income by Division See PMCB's Income by Division


PMCB Annual Return On Investment (Apr 30 2026)
2026		 (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022
Total Investments in Millions 44 52 52 73 90
Y / Y Investment Growth -15.33 % -0.44 % -27.8 % -19.16 % 1246.21 %
Net Income in Millions -19 27 -2 -4 -4
Y / Y Net Income Growth - - - - -
Annual Return On Investment -43.91 % 50.82 % -4.16 % -5.94 % -4.71 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
PMCB's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for PMCB's Competitors
Subscribers only: Roi for Pharmacyte Biotech Inc's Suppliers
Subscribers only: Return On Investment for PMCB's Customers

Other Ratios
PMCB's Roa PMCB's Inventory Turnover Ratio PMCB's Growth Rates PMCB's Dividend Statistics
PMCB's Profitability Ratios PMCB's Asset Turnover Ratio PMCB's Dividend Growth
PMCB's Roe PMCB's Valuation Ratios PMCB's Financial Strength Ratios PMCB's Dividend Payout Ratio



Companies with similar Return On Investment at Jul 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-15T12:00:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.